Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Nadya Tarasova · DIVISION OF BASIC SCIENCES - NCI · 2023 · $40,169 — The reliability, and consequently success of virtual screening depends heavily on the accuracy of the x-ray structure depiction of the target protein structure in solution. Crystal packing can distort conformation of flexible parts of the protein thus leading to misrepresentation of the protein stru…
Mary N. Carrington · DIVISION OF BASIC SCIENCES - NCI · 2023 · $127,700 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing COVID-19 pandemic. The pandemic's impact has spurred research into the pathogenesis, diagnosis, treatment, and prevention of SARS-CoV-2 and its emerging variants of concern. Prior studies have elucidated the …
eric freed · DIVISION OF BASIC SCIENCES - NCI · 2023 · $54,403 — In a structural and functional analysis of the SARS-CoV-2 S protein that we recently started, we have determined that MARCH8, but not a catalytically inactive MARCH8 mutant, targets the S proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2 for degradation. We also showed that human airway epithelial cell…
JAMES L ARTHOS · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $109,700 — Intranasal administration led to rapid lung alveolar macrophage uptake, pulmonary vascular leakage, and neutrophil recruitment and damage. Exposure to the spike protein enhanced neutrophil NETosis and augmented human macrophage TNF- and IL-6 production. Human and murine immune cells employed C-type …
Joshua Hoong Yu Tan · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $568,478 — The overarching goal of this project is to study the immune response to COVID-19 at the monoclonal level to increase our understanding of basic biology and develop new tools to combat disease. We have screened plasma from >100 acutely infected and convalescent COVID-19 individuals for neutralization…
Patrizia Farci · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $47,982 — 1. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants A. Generation and characterization of anti-SARS-CoV-2 mAbs using phage-display libraries from COVID-19 convalescent patients. Peripheral blood samples were collected from 12 convalescent COVID-19 patients…
David Sacks · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $114,312 — Our initial experiments involving the transgenic L. major lines overexpressing spike protein, either the full length S gene sequence or secreted S1/S2 subunits, showed that in each case the clones were attenuated in mice. New transgenic lines were generated: the full length S gene sequence was ampl…
Clare Michal Waterman · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2023 · $1,036,270 — Project: MARK2/Par1b regulates cytoskeleton polarization and directed cell migration through modulation of Myosin II contractility and focal adhesion organization. Personnel: Ana Pasapera Collaborators: Sarah Heissler, Masumi Eto Goal: We sought to test the hypothesis that MARK2 mediates polariza…
Duane R. Wesemann · BRIGHAM AND WOMEN'S HOSPITAL · 2023 · $3,175,901 — PROJECT 1 SUMMARY Global establishment of Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is a continued human threat. While successful vaccine programs are well underway, genetic drift and immune escape have already begun to subvert immunity. In addition, related zoonotic coronaviruses…
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $253,527 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
Ali Hassan Ellebedy · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $208,535 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
Devdoot Majumdar · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · 2023 · $226,930 — PROJECT SUMMARY: Devdoot Majumdar, PhD, Research Project Leader (RPL) The mRNA vaccines against SARS-CoV-2 proved unexpectedly efficacious, but also require a series of booster immunizations to remain protective. Global deployment of these vaccines has been slow, particularly in low- and middle-inco…
Kevin Wiehe · DUKE UNIVERSITY · 2023 · $2,828,814 — Abstract – Project 2 Animal betacoronaviruses (betaCoVs), such as those that gave rise to SARS-CoV-1, MERS, and now SARS- CoV-2, represent a significant, continuous threat to human health. Vaccines can provide pre-existing immunity to future zoonotic coronaviruses. A major limitation of the current …
Rory Henderson · DUKE UNIVERSITY · 2023 · $966,626 — Abstract - Project 4 SARS-CoV-2, a member of the genus Betacoronavirus (betaCoV), is the third major zoonotic outbreak of a highly pathogenic betaCoV in the last two decades. We propose to design vaccines to contribute to the global effort to counter the COVID-19 pandemic as swiftly as possible, and…
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $175,000 — The emergence of the Wuhan new coronavirus (nCoV) initiated efforts to rapidly develop effective medical countermeasures including vaccines and therapeutics against this severe disease. However, there is limited knowledge on polyclonal antibody responses generated following vaccination or nCoV infec…
JUN WANG · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 · $211,875 — Project Summary The rapid spread of SARS-CoV-2 and the resulting Coronavirus Disease 2019 (COVID-19) pose a global pandemic. SARS-CoV-2 and its family members share some puzzling, unique pathological features, most notably acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), …
Zhuo Li · CYANVAC, LLC · 2022 · $150,000 — Developing a liquid formulation for CVXGA1 COVID-19 intranasal vaccine ABSTRACT In this Phase I SBIR application, we propose to develop a liquid formulation for CVXGA1 COVID-19 intranasal vaccine. The ongoing global coronavirus disease 2019 (COVID-19) pandemic has resulted in the loss of many lives …
Dan H. Barouch · FRED HUTCHINSON CANCER CENTER · 2022 · $5,663,427 — NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO…
Peter B. Gilbert · FRED HUTCHINSON CANCER CENTER · 2022 · $260,795 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial entitled “A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficac…
Thomas Parks Remcho · TULANE UNIVERSITY OF LOUISIANA · 2024 · $53,167 — Pneumonia is the leading killer of children globally and a significant cause of morbidity and mortality in the US. Pneumonias due to drug-resistant Enterobacteriaceae are an emerging problem. Our lab has shown that lung tissue resident memory (TRM) cells, consisting of Th17 and Th1 cells, provide pr…